Phase 3Completed
The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study
- Sponsor
- AstraZeneca (Industry)
- Enrollment
- 10 planned
- Conditions
- Hypercholesterolemia
- Interventions
- Rosuvastatin; aortic pulse wave velocity measurements
- Ages
- adults, older adults
- Registry
- NCT00240279
Full record on ClinicalTrials.gov
From the registry
To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)
Primary outcomes
- To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)
History
Last registry update
Primary completion
Registered
Started